Table 4 Proportion of patients stratified by age group, sex, and treatment group (“concomitant LABA and ICS users”, “switchers”, “non-concomitant LABA and ICS users”, “LABA users without ICS”, “ICS users without LABA”) for the year 2008*
From: Prescribing of long-acting beta-2-agonists/inhaled corticosteroids after the SMART trial
Age group | Concomitant LABA and ICS users | Switchers | Non-concomitant LABA and ICS users | LABA users without ICS | ICS users without LABA | All LABA/ICS treatment categories | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Male | Female | Male | Female | Male | Female | Male | Female | Male | Female | Male | Female | |
0-9 | 4,242 (25.2%) | 2,288 (24.2%) | 103 (0.6%) | 53 (0.6%) | 36 (0.2%) | 20 (0.2%) | 95 (0.6%) | 32 (0.3%) | 12,376 (73.4%) | 7,053 (74.7%) | 16,852 (100%) | 9,446 (100%) |
10-19 | 10,347 (56.9%) | 7,060 (56.1%) | 247 (1.4%) | 151 (1.2%) | 60 (0.3%) | 47 (0.4%) | 434 (2.4%) | 294 (2.3%) | 7,095 (39.0%) | 5,035 (40.0%) | 18,183 (100%) | 12,587 (100%) |
20-29 | 6,660 (63.6%) | 8,014 (60.8%) | 214 (2.0%) | 329 (2.5%) | 23 (0.2%) | 48 (0.4%) | 448 (4.3%) | 401 (3.0%) | 3,123 (29.8%) | 4,385 (33.3%) | 10,468 (100%) | 13,177 (100%) |
30-39 | 7,972 (62.5%) | 10,363 (58.7%) | 386 (3.0%) | 585 (3.3%) | 54 (0.4%) | 101 (0.6%) | 579 (4.5%) | 698 (4.0%) | 3,758 (29.5%) | 5,914 (33.5%) | 12,749 (100%) | 17,661 (100%) |
40-49 | 11,503 (63.2%) | 16,413 (60.4%) | 790 (4.3%) | 1,129 (4.2%) | 95 (0.5%) | 179 (0.7%) | 904 (5.0%) | 1,224 (4.5%) | 4,916 (27.0%) | 8,222 (30.3%) | 18,208 (100%) | 27,167 (100%) |
50-59 | 10,310 (62.4%) | 15,611 (60.0%) | 1,000 (6.1%) | 1,494 (5.7%) | 112 (0.7%) | 209 (0.8%) | 1,126 (6.8%) | 1,436 (5.5%) | 3,962 (24.0%) | 7,261 (27.9%) | 16,510 (100%) | 26,011 (100%) |
60-69 | 12,488 (61.6%) | 16,885 (59.7%) | 1,659 (8.2%) | 1,921 (6.8%) | 148 (0.7%) | 242 (0.9%) | 1,779 (8.8%) | 1,794 (6.3%) | 4,208 (20.7%) | 7,464 (26.4%) | 20,282 (100%) | 28,306 (100%) |
70-79 | 11,291 (61.7%) | 14,340 (60.9%) | 1,673 (9.1%) | 1,780 (7.6%) | 180 (1.0%) | 229 (1.0%) | 1,868 (10.2%) | 1,770 (7.5%) | 3,294 (18.0%) | 5,445 (23.1%) | 18,306 (100%) | 23,564 (100%) |
80-89 | 4,071 (64.0%) | 6,632 (63.3%) | 547 (8.6%) | 777 (7.4%) | 44 (0.7%) | 102 (1.0%) | 766 (12.0%) | 972 (9.3%) | 934 (14.7%) | 1,986 (19.0%) | 6,362 (100%) | 10,469 (100%) |
90+ | 204 (65.2%) | 465 (63.1%) | 22 (7.0%) | 39 (5.3%) | 0 | 7 (0.9%) | 45 (14.4%) | 84 (11.4%) | 42 (13.4%) | 142 (19.3%) | 313 (100%) | 737 (100%) |
Total | 79,088 (57.2%) | 98,071 (58.0%) | 6,641 (4.8%) | 8,258 (4.9%) | 752 (0.5%) | 1,184 (0.7%) | 8,044 (5.8%) | 8,705 (5.1%) | 43,708 (31.6%) | 52,907 (31.3%) | 138,233 (100%) | 169,125 (100%) |